EP1341543A4 - METHODS INVOLVING DEFINED OXIDE PHOSPHOLIPIDS, AND COMPOSITIONS CONTAINING THE SAME, FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS - Google Patents

METHODS INVOLVING DEFINED OXIDE PHOSPHOLIPIDS, AND COMPOSITIONS CONTAINING THE SAME, FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

Info

Publication number
EP1341543A4
EP1341543A4 EP01997274A EP01997274A EP1341543A4 EP 1341543 A4 EP1341543 A4 EP 1341543A4 EP 01997274 A EP01997274 A EP 01997274A EP 01997274 A EP01997274 A EP 01997274A EP 1341543 A4 EP1341543 A4 EP 1341543A4
Authority
EP
European Patent Office
Prior art keywords
atherosclerosis
prevention
treatment
compositions containing
methods employing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01997274A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1341543A2 (en
Inventor
Dror Harats
Jacob George
Gideon Halperin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Notable Labs Ltd
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22956589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1341543(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Priority to EP11189562A priority Critical patent/EP2425841A1/en
Publication of EP1341543A2 publication Critical patent/EP1341543A2/en
Publication of EP1341543A4 publication Critical patent/EP1341543A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1787—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings and having unsaturation outside the aromatic rings
EP01997274A 2000-11-24 2001-11-22 METHODS INVOLVING DEFINED OXIDE PHOSPHOLIPIDS, AND COMPOSITIONS CONTAINING THE SAME, FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS Withdrawn EP1341543A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11189562A EP2425841A1 (en) 2000-11-24 2001-11-22 Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25257400P 2000-11-24 2000-11-24
US252574P 2000-11-24
PCT/IL2001/001080 WO2002041827A2 (en) 2000-11-24 2001-11-22 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
EP1341543A2 EP1341543A2 (en) 2003-09-10
EP1341543A4 true EP1341543A4 (en) 2009-09-02

Family

ID=22956589

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11189562A Withdrawn EP2425841A1 (en) 2000-11-24 2001-11-22 Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
EP01997274A Withdrawn EP1341543A4 (en) 2000-11-24 2001-11-22 METHODS INVOLVING DEFINED OXIDE PHOSPHOLIPIDS, AND COMPOSITIONS CONTAINING THE SAME, FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11189562A Withdrawn EP2425841A1 (en) 2000-11-24 2001-11-22 Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis

Country Status (9)

Country Link
EP (2) EP2425841A1 (es)
JP (3) JP4162486B2 (es)
KR (1) KR100865142B1 (es)
CN (1) CN100577174C (es)
AU (2) AU1846102A (es)
CA (1) CA2429817C (es)
IL (1) IL156015A0 (es)
MX (1) MXPA03004517A (es)
WO (1) WO2002041827A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU1846102A (en) * 2000-11-24 2002-06-03 Cardimmune Ltd Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis
WO2004006910A1 (de) * 2002-07-15 2004-01-22 Norbert Leitinger Lipidoxidationsprodukte zur hemmung von entzündungen
EP2574612A1 (en) * 2004-07-09 2013-04-03 Vascular Biogenics Ltd. Improved process for the preparation of oxidized phospholipids
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
AU2007200090B2 (en) * 2004-07-09 2011-09-22 Vascular Biogenics Ltd. Improved Process for the Preparation of Oxidized Phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
KR101159406B1 (ko) * 2008-03-17 2012-06-28 이화여자대학교 산학협력단 혈관 재협착방지 스텐트 코팅용 조성물 및 이를 이용해 제조된 스텐트
NZ619895A (en) 2008-08-12 2015-12-24 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
US9206206B2 (en) * 2008-11-06 2015-12-08 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
BR112012016543A2 (pt) * 2010-01-05 2015-09-01 Vascular Biogenics Ltd Tratamento com vb-201
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
CN103874485B (zh) 2011-09-01 2017-06-09 脉管生物生长有限公司 氧化的磷脂的制剂和剂型
BR112014031086A2 (pt) * 2012-06-11 2017-06-27 Cleveland Clinic Found tratamento e prevenção de doenças cardiovasculares e trombose
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
EP3223824B1 (en) 2014-11-26 2021-01-06 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0121088A1 (en) * 1983-03-05 1984-10-10 A. Nattermann & Cie. GmbH New o-acyl-alkanediol-phospholipids, processes for their preparation and pharmaceutical preparations containing them
EP0142333A2 (en) * 1983-11-08 1985-05-22 Ono Pharmaceutical Co., Ltd. Glycerol derivatives
WO1987005904A1 (en) * 1986-03-24 1987-10-08 The University Of Sydney Antigenic analogues of platelet activating factor (paf)
JPS6354386A (ja) * 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPH01258691A (ja) * 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
ES2019552A6 (es) * 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
WO1995023592A1 (en) * 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60104066A (ja) * 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
EP0225129B1 (en) 1985-11-29 1989-05-24 Takeda Chemical Industries, Ltd. Phospholipid derivatives, their production and use
US5561052A (en) 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
EP0742822B1 (en) 1994-01-31 2004-09-22 The Institute of Cancer Research: Royal Cancer Hospital Folding proteins
JP3364313B2 (ja) * 1994-03-22 2003-01-08 株式会社トクヤマ ポルフィリン／インジウム錯体及び陰イオン感応膜
US6156500A (en) 1995-02-10 2000-12-05 Millennium Pharmaceuticals, Inc. Methods for the treatment and diagnosis of cardiovascular disease
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US6261597B1 (en) 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6034102A (en) 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US5935577A (en) 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US5945308A (en) 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US6701176B1 (en) 1998-11-04 2004-03-02 Johns Hopkins University School Of Medicine Magnetic-resonance-guided imaging, electrophysiology, and ablation
AU1846102A (en) * 2000-11-24 2002-06-03 Cardimmune Ltd Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0121088A1 (en) * 1983-03-05 1984-10-10 A. Nattermann & Cie. GmbH New o-acyl-alkanediol-phospholipids, processes for their preparation and pharmaceutical preparations containing them
EP0142333A2 (en) * 1983-11-08 1985-05-22 Ono Pharmaceutical Co., Ltd. Glycerol derivatives
WO1987005904A1 (en) * 1986-03-24 1987-10-08 The University Of Sydney Antigenic analogues of platelet activating factor (paf)
JPS6354386A (ja) * 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPH01258691A (ja) * 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
ES2019552A6 (es) * 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
WO1995023592A1 (en) * 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DEIGNER H P ET AL: "Effect of platelet activating factor on the kinetics of LDL oxidation in vitro", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 317, no. 3, 15 February 1993 (1993-02-15), pages 202 - 206, XP025615837, ISSN: 0014-5793, [retrieved on 19930215] *
ITABE H ET AL: "Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 27 DEC 1996, vol. 271, no. 52, 27 December 1996 (1996-12-27), pages 33208 - 33217, XP002532604, ISSN: 0021-9258 *
ITABE H ET AL: "Preparation of radioactive aldehyde-containing phosphatidylcholine.", ANALYTICAL BIOCHEMISTRY 1 OCT 2000, vol. 285, no. 1, 1 October 2000 (2000-10-01), pages 151 - 155, XP002532603, ISSN: 0003-2697 *
KAMIDO H ET AL: "LIPID ESTER-BOUND ALDEHYDES AMONG COPPER-CATALYZED PEROXIDATION PRODUCTS OF HUMA PLASMA LIPOPROTEINS", JOURNAL OF LIPID RESEARCH, BETHESDA, MD, US, vol. 36, 1 January 1995 (1995-01-01), pages 1876 - 1886, XP002951008, ISSN: 0022-2275 *
KERN H ET AL: "STIMULATION MONOCYTTS AND PLATELETS BY SHORT-CHAIN PHOSPHATIDYLCHOLINES WITH AND WITHOUT TERMINAL CARBOXYL GROUP", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1394, no. 1, 1 January 1998 (1998-01-01), pages 33 - 42, XP000938800, ISSN: 0167-4889 *
LEITINGER N ET AL: "STRUCTURALLY SIMILAR OXIDIZED PHOSPHOLIPIDS DIFFERENTIALLY REGULATE ENDOTHELIAL BINDING OF MONOCYTES AND NEUTROPHILS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 96, no. 21, 12 October 1999 (1999-10-12), pages 12010 - 12015, XP002951991, ISSN: 0027-8424 *
SUBBANAGOUNDER G ET AL: "DETERMINANTS OF BIOACTIVITY OF OXIDIZED PHOSPHOLIPIDS SPECIFIC OXIDIZED FATTY ACYL GROUPS AT THE SN-2 POSITION", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, LIPPINCOTT WILLIAMS & WILKINS, no. 20, 1 January 2000 (2000-01-01), pages 2248 - 2254, XP002951986, ISSN: 1079-5642 *

Also Published As

Publication number Publication date
WO2002041827A3 (en) 2002-10-10
CA2429817A1 (en) 2002-05-30
KR100865142B1 (ko) 2008-10-24
WO2002041827A9 (en) 2003-05-30
AU2002218461B2 (en) 2006-09-07
CN100577174C (zh) 2010-01-06
AU1846102A (en) 2002-06-03
IL156015A0 (en) 2003-12-23
JP2004537498A (ja) 2004-12-16
KR20030077543A (ko) 2003-10-01
JP2012149075A (ja) 2012-08-09
JP2008222726A (ja) 2008-09-25
EP1341543A2 (en) 2003-09-10
WO2002041827A2 (en) 2002-05-30
EP2425841A1 (en) 2012-03-07
JP5001906B2 (ja) 2012-08-15
MXPA03004517A (es) 2004-03-26
CA2429817C (en) 2013-02-12
JP4162486B2 (ja) 2008-10-08
CN1529605A (zh) 2004-09-15

Similar Documents

Publication Publication Date Title
IL156015A0 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002218461A1 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
HK1040944A1 (en) Methods and compositions for the prevention and treatment of anemia
IL156770A0 (en) Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
AU8657601A (en) Composition and method for treatment of hypertriglyceridemia
HK1094909A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18
EP1162934A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING PHOTOVAGENING
EP1309552A4 (en) COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
IL176976A0 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU3712500A (en) Compositions and methods for treatment of epilepsy
HK1041878A1 (zh) 二羥吡啶化合物和其用作鉀通道開放劑的用途
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
GB0105472D0 (en) Smoke composition and method of use thereof
IL125316A0 (en) Novel compositions for treatment of atherosclerosis and related conditions
EP1305017A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
AU2001247546A1 (en) Method and composition for treatment and prevention of alopecia
PL349587A1 (en) Fire-proof cable tray and method of mounting same
AU7223401A (en) Compounds and inhibitors of phospholipases
AU4299901A (en) Composition for treating friction pairs and method of its preparation
SI1305286T1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
HU9900843D0 (en) Preventive and/or decreasing emulsion for formation of lime-scale
SI1126867T1 (en) A composition for the prevention and/or treatment of atherosclerosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030530

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20090618BHEP

Ipc: C07C 59/235 20060101ALI20090618BHEP

Ipc: C07F 9/02 20060101ALI20090618BHEP

Ipc: A61K 31/08 20060101ALI20090618BHEP

Ipc: A61K 31/075 20060101ALI20090618BHEP

Ipc: A61K 31/11 20060101ALI20090618BHEP

Ipc: A61K 31/12 20060101ALI20090618BHEP

Ipc: A61K 31/20 20060101ALI20090618BHEP

Ipc: A61K 31/19 20060101ALI20090618BHEP

Ipc: A61K 31/24 20060101ALI20090618BHEP

Ipc: A61K 31/215 20060101ALI20090618BHEP

Ipc: A61K 31/685 20060101AFI20021028BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090803

17Q First examination report despatched

Effective date: 20091109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130522

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1056688

Country of ref document: HK